FOR IMMEDIATE RELEASE

BIOCLINICA, INC. TO PARTICIPATE IN UPCOMING CLINICAL TRIAL INDUSTRY EVENTS AND DEMONSTRATE ITS TECHNOLOGY–ENHANCED CAPABILITIES

NEWTOWN, PA, June 6, 2011 – BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that it will attend, participate in, and speak at the following industry conferences in June and July. BioClinica experts will discuss industry trends and also demonstrate its portfolio of technologies and solutions.

ASCO Annual Meeting
June 3-7, 2011
Chicago, IL
Booth # 22082

With more than 20 years of experience, BioClinica has broad expertise in global oncology clinical trials. As a leading provider of technology-enhanced clinical trial management services, BioClinica will demonstrate the ways in which its experience and scientific resources help to ensure that clinical trial processes are efficient and well-managed.

5th Osteoarthritis Imaging Workshop
June 8 – 11, 2011
Salzburg, Austria

BioClinica will be a sponsor and participant at this important international workshop focused on scientific discussions about the clinical application and validation of imaging biomarkers related to Osteoarthritis research.

DIA 2011 47th Annual Meeting
June 19-23, 2011
Chicago, IL
Booth #1417

This meeting is the premier event for professionals involved in the discovery, development and life cycle management of pharmaceuticals, medical devices, and related products. On Tuesday, June 21, at 3:30 PM, Jonathan R. Andrus, MS, Vice President, Data and Study Operations for BioClinica, will chair a session entitled “Hot Topics in eClinical.” This interactive showcase will discuss topics related to eClinical-based approaches for improving data quality, developing protocols, clinical trial planning and risk-based approaches, and how they can influence the role of monitoring.

-- more --
AAICAD 2011
Alzheimer’s Association International Conference on Alzheimer’s Disease 2011
July 16-21, 2011
Paris, France
Booth #106

AAICAD is the world’s leading forum on dementia research and provides leaders in the field a venue for learning and networking. BioClinica will demonstrate its advanced imaging capabilities and share information about its scientific resources in four poster presentations, including: “Whole-Brain and Ventricular Volume Change Measurement in Multicenter Clinical Trials: a Feasibility Study of Jacobian Integration using ADNI Data,” and “High-Throughput and Accurate Segmentation of Lateral Ventricles Using Combined Single Atlas Propagation and Tissue Classification: Application to ADNI and IBSR Data.”

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

####